research report · TMO

Thermo Fisher Scientific Inc.

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 1, 2026 from its quarterly report (10-Q for the quarter ended Sep 26, 2026, filed Oct 30, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Improving

better on balance: sales, margins, cash or competitive position

financial resilience

Strong

can meet its obligations and fund its plan for two years with money it can count on, with room

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

Thermo Fisher's core business is getting stronger. Organic revenue growth (growth excluding acquisitions, divestitures and currency) reached 6% in the third quarter of 2026, against 2% for all of 2025, and nine-month free cash flow rose 39% to $4.62B. The quarter overstates the run-rate. Management attributes 50 of the 120 basis points of adjusted margin gain to one-time tariff refunds and calls part of the pharma services strength timing pulled forward from the fourth quarter. Adjusted earnings also include a $161M discrete tax benefit. Debt rose to $41.4B after the $9.1B Clario purchase and $4.0B of buybacks, but operating cash covers capital spending, dividends and maturities with room.

what changed this quarter

  • Third-quarter revenue was $12.14B, up 9% (6% organic). GAAP diluted EPS was $4.64 (+9%) and adjusted EPS $6.68 (+15%) versus Q3 2025.
  • Adjusted operating margin was 24.5% versus 23.3%; GAAP operating margin was 18.6% versus 17.4%.
  • 2026 guidance was raised: revenue $47.7B–$48.2B, organic growth 4%, adjusted EPS $25.13–$25.43 (up 15 cents at the midpoint), free cash flow $7.0B–$7.5B.
  • The microbiology business was sold August 12 for about $1.07B in cash and a promissory note. A pharma services plant was agreed for sale September 4, with a $244M loss.
  • There were no buybacks in the quarter and $1.00B of authorization remains. Total debt was $41.37B versus $39.38B at year-end.

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • Organic growth is accelerating, but Q3's 6% overstates the run-rate
  • About 40% of the margin expansion is a one-time tariff refund
  • Adjusted earnings lean on recurring "discrete" tax benefits
  • Debt-funded deals have thinned the balance-sheet cushion

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what TMO files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on TMO say?” Add Viridis to Claude, or to ChatGPT.